Advertisement

Novavax's Late-Stage COVID Vaccine Trial in U.S. Delayed Again: Should Investors Worry?

Novavax's Late-Stage COVID Vaccine Trial in U.S. Delayed Again: Should Investors Worry?

On Monday, the biotech announced another delay in the initiation of a U.S. late-stage study evaluating COVID-19 vaccine candidate NVX-CoV2373. Novavax initially expected to begin its U.S. phase 3 study of NVX-CoV2373 in October. For the last month, Novavax has stated that it would initiate the U.S. phase 3 clinical trial by the end of November.